Breast最新文献

{"title":"What can paintings teach us?","authors":"Marcin Śniadecki, Anna Malitowska, Oliwia Musielak, Zuzanna Boyke, Cynthia Aristei","doi":"10.1016/j.breast.2025.103882","DOIUrl":"https://doi.org/10.1016/j.breast.2025.103882","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"103882"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative","authors":"Jan Henkel ,&nbsp;Andreas Laner ,&nbsp;Melanie Locher ,&nbsp;Tobias Wohlfrom ,&nbsp;Birgit Neitzel ,&nbsp;Kerstin Becker ,&nbsp;Teresa Neuhann ,&nbsp;Angela Abicht ,&nbsp;Verena Steinke-Lange ,&nbsp;Barbara Klink ,&nbsp;Birgit Eichhorn ,&nbsp;Winfried Schmidt ,&nbsp;Daniel Berner ,&nbsp;Anna Teubert ,&nbsp;Anne Holtorf ,&nbsp;Sarah Heinrich ,&nbsp;Gabriele Wildhardt ,&nbsp;Martin Schulze ,&nbsp;Laura von der Heyden ,&nbsp;Konstanze Hörtnagel ,&nbsp;Elke Holinski-Feder","doi":"10.1016/j.breast.2025.103887","DOIUrl":"10.1016/j.breast.2025.103887","url":null,"abstract":"<div><div>As multigene panel testing is becoming routine in clinical care, there are recommendations at national and international level, as to which genes should be analyzed in the context of a hereditary breast and ovarian cancer (HBOC). However, the individual composition of gene panels offered by testing laboratories vary, resulting in a different variant diagnostic rate. Therefore, we performed a retrospective NGS dataset analysis of suspected HBOC patients who had been tested at different German diagnostic laboratories that are part of the NASGE network.</div><div>We collected 29,317 HBOC datasets and compared the diagnostic yield applying the most common panel recommendations and an internal HBOC gene panel. Additionally, we analyzed the data concerning other potential tumor risk syndromes (TRS) not caused by pathogenic variants in the core panel genes.</div><div>At least one pathogenic variant causative for an autosomal-dominant TRS was identified in 4235 datasets, resulting in an overall diagnostic yield of 14.4 %. The diagnostic yield of pathogenic variants varied depending on the applied HBOC panel (between 5 and 26 genes) from 9.0 % to 13.8 % with the internal HBOC panel having a yield of 12.7 %. Notably, in about 1 % of cases, a pathogenic variant outside the established HBOC core genes was identified, indicating the presence of other TRS.</div><div>These results are consistent with previous observations that a significant proportion of patients with HBOC predisposition were not detected by the guideline-based gene panels and suggest that expanded diagnostics compared to currently recommended multigene panels may identify additional patients at high risk for developing cancer.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103887"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy","authors":"Meritxell Arenas ,&nbsp;Yasemin Bölükbaşı ,&nbsp;Liesbeth J. Boersma ,&nbsp;Birgitte Offersen ,&nbsp;Vassilis Kouloulias ,&nbsp;Isabella Palumbo ,&nbsp;Lurdes Trigo ,&nbsp;Laura Lozza ,&nbsp;Fabio Marazzi ,&nbsp;Marco Trovo ,&nbsp;Sofia Rivera ,&nbsp;Orit Kaidar-Person ,&nbsp;Charlotte Coles ,&nbsp;Icro Meattini ,&nbsp;Vincenzo Valentini ,&nbsp;Cynthia Aristei ,&nbsp;Philip Poortmans","doi":"10.1016/j.breast.2025.103881","DOIUrl":"10.1016/j.breast.2025.103881","url":null,"abstract":"<div><div>At the Fifth Assisi Think Tank Meeting (ATTM) on breast cancer, one key topic was the role of tumor bed boost in invasive breast cancer and ductal carcinoma in situ. The need for a tumor bed boost after whole breast irradiation is controversial. A literature review assessed boost indications, target volume definition, techniques, dose fractionation, and ongoing trials. Findings indicated that while a boost halves the risk of local recurrence at 10 years, it also leads to worsened cosmetic outcomes and increased fibrosis without improving overall survival. Therefore, we would recommend to omit the boost if the estimated reduction in local recurrence at 10 years is less than 3 %, and to apply shared decision-making with patients, if the boost is expected to reduce the local recurrence rate with &gt;3 % at 10 years. Future research will focus on identifying patient subgroups that can safely omit the boost and improving boost volume precision.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103881"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interhospital variation in surgical treatment of screen-detected breast cancer in the South of the Netherlands","authors":"Eline L. van der Veer ,&nbsp;Angela M.P. Coolen ,&nbsp;Adriana M.J. Bluekens ,&nbsp;Manon I. Generaal ,&nbsp;Robert-Jan Schipper ,&nbsp;Wikke Setz-Pels ,&nbsp;Dominique J.P. van Uden ,&nbsp;Adri C. Voogd ,&nbsp;Lucien E.M. Duijm","doi":"10.1016/j.breast.2025.103886","DOIUrl":"10.1016/j.breast.2025.103886","url":null,"abstract":"<div><h3>Background</h3><div>The effectiveness of the Dutch breast cancer screening programme depends on the quality of the full trajectory, from the first screening to the final treatment of a screen-detected breast cancer. Interhospital variation in breast cancer treatment has been explored by several studies, however, not specifically in a screen-detected breast cancer population. The current study compares the treatment strategies of women with screen-detected breast cancer between hospitals in the South of the Netherlands.</div></div><div><h3>Methods</h3><div>A total of 1450 women with screen-detected breast cancer, who participated in the Dutch screening programme between January 2009 and July 2019, were included in this retrospective analysis of a prospectively obtained database. Breast cancer treatment (i.e. preoperative MRI, neoadjuvant systemic therapy and type and outcomes of surgery) was compared between hospitals using multivariate analysis.</div></div><div><h3>Results</h3><div>Statistically significant interhospital variation was observed in the use of preoperative MRI (range 20.8–35.8 %, p &lt; 0.001), neoadjuvant systemic therapy (range 4.0–13.3 %, p &lt; 0.001) and breast conserving surgery (range 70.0–87.1 %, p &lt; 0.001). These differences persisted after adjustment for case-mix. In patients with invasive breast cancer treated by breast conserving surgery, the mean volume of the resection specimen ranged from 381 to 541 ml between hospitals (p &lt; 0.001). However, this was not accompanied by significant differences in the percentage of patients with positive resection margins (range 2.9–5.7 %, p = 0.34).</div></div><div><h3>Conclusions</h3><div>We observed significant interhospital variation in the management of women with screen-detected breast cancer. Quality assurance in screen-detected breast cancer may reduce these differences, but evolving breast cancer care and more personalised approaches should be accounted for.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103886"},"PeriodicalIF":5.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143027979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of adverse childhood experiences on pain and subjective cognitive decline in patients treated for localized breast cancer: The mediating role of sense of coherence, sense of danger and psychosocial distress and danger","authors":"Efrat Sher-Censor ,&nbsp;Margrita Makarov ,&nbsp;Ayelet Shai","doi":"10.1016/j.breast.2025.103884","DOIUrl":"10.1016/j.breast.2025.103884","url":null,"abstract":"<div><h3>Background</h3><div>Pain and subjective cognitive decline (SCD) are common sequala of breast cancer (BC) treatment. Adverse childhood experiences (ACEs) are associated with pain and adverse health outcomes in noncancer population. Sense of coherence (SOC) reflects the disposition that life is manageable and predictable. Sense of danger (SOD) is the extent of perceived danger to oneself and family from a specific stressor. We aimed to assess if ACEs are associated with pain and SCD in patients treated for localized BC, and whether decreased SOC, increased SOD from BC, and increased psychological distress mediate these links.</div></div><div><h3>Methods</h3><div>This study is a primary analysis of an on-going prospective trial, recruiting patients with localized BC before (neo) adjuvant oncological therapy. Patients completed validated questionnaires on ACEs, pain, SCD, SOC, SOD, and psychosocial distress. Demographic and clinical data were also collected.</div></div><div><h3>Results</h3><div>We performed an analysis of baseline assessments in 127 patients. After controlling for demographic and clinical factors that correlated with study variables, serial mediation analyses confirmed that ACEs were associated with increased pain and SCD. These links were mediated by decreased SOC, followed by increased SOD, followed by increased psychosocial distress (all p's &lt; 0.001). The models explained 50.14 % of the variance in pain and 43.37 % of the variance in SCD.</div></div><div><h3>Conclusion</h3><div>Our study suggests that ACEs increase the risk of pain and SCD in patients with localized BC, mediated by SOC, SOD, and psychosocial distress. These factors should be addressed when aiming to reduce symptom burden in BC patients.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103884"},"PeriodicalIF":5.7,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143027980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and temporal patterns of true recurrences and second primaries in women with breast cancer: A 10-year competing risk-adjusted analysis","authors":"Silvia Mancini ,&nbsp;Lauro Bucchi ,&nbsp;Annibale Biggeri ,&nbsp;Orietta Giuliani ,&nbsp;Flavia Baldacchini ,&nbsp;Alessandra Ravaioli ,&nbsp;Federica Zamagni ,&nbsp;Fabio Falcini ,&nbsp;Rosa Vattiato","doi":"10.1016/j.breast.2025.103883","DOIUrl":"10.1016/j.breast.2025.103883","url":null,"abstract":"<div><h3>Introduction</h3><div>We report a population-based, competing risk-adjusted analysis of the risk and timing of true recurrences and second primaries in women with breast cancer (BC), that are still ill-defined.</div></div><div><h3>Methods</h3><div>We performed a manual review of medical charts of 1988 BC patients from a cancer registry in northern Italy (2000–2013). The occurrence and timing of true recurrences (TRs, including local, regional and distant recurrences) and second BCs (SBCs, including ipsilateral and contralateral SBC) during 10 years of follow-up were evaluated. The prognostic factors for TRs and SBCs were identified using the Fine and Gray model.</div></div><div><h3>Results</h3><div>The cumulative incidence was 13.7 % (95 % confidence interval (CI), 12.2–15.3 %) for TRs and 4.6 % (95 % CI, 3.7–5.7 %) for SBCs. The median time to detection varied between 3.4 (TRs) and 5.1 (SBCs) years. The risk of TRs had two peaks, one between the 2nd and the 3rd year of follow-up and another between the 7th and the 8th year. The subhazard of SBCs fluctuated for five years, had a drop between the 6th and the 7th year and a marked peak between the 8th and the 9th year. Prognostic factors for TRs (tumour stage and grade, lymph node status and residual disease) and SBCs (patient age and –inverse association– hormone therapy) were different. In the 9th-10th year of follow-up, the excess incidence of total BC episodes as compared with the expected incidence of BC was no longer significant (standardised incidence ratio, 1.15; 95 % CI, 0.86–1.53).</div></div><div><h3>Conclusions</h3><div>The multifaceted results of this study warrant further research into the risk and timing of all types of BC recurrence.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103883"},"PeriodicalIF":5.7,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical treatment after neoadjuvant systemic therapy for HER2-positive invasive breast cancer in the Netherlands: 10-Year trends and the influence an accompanying DCIS component","authors":"Roxanne A.W. Ploumen ,&nbsp;Thiemo J.A. van Nijnatten ,&nbsp;Loes F.S. Kooreman ,&nbsp;Adri C. Voogd ,&nbsp;Kristien B.M.I. Keymeulen ,&nbsp;Sabine Siesling ,&nbsp;Marjolein L. Smidt","doi":"10.1016/j.breast.2024.103854","DOIUrl":"10.1016/j.breast.2024.103854","url":null,"abstract":"<div><h3>Background</h3><div>The presence of a DCIS component accompanying invasive breast cancer (IBC) is associated with a higher rate of primary mastectomy compared to IBC without DCIS. After neoadjuvant systemic therapy (NST), HER2+ IBC patients show high response rates, allowing for increasing breast-conserving surgery rates. The aim of this study was to examine surgical trends after NST in a Dutch nationwide HER2+ cohort, and the influence of a DCIS component on mastectomy rate.</div></div><div><h3>Methods</h3><div>Women with HER2+ IBC, diagnosed between 2010 and 2019 and treated with NST and surgery were included from the Netherlands Cancer Registry. Mastectomy rate was examined over the years, and compared between patients with and without a DCIS component in the pre-NST biopsy. Multivariable logistic regression analysis was used to investigate the association of the DCIS component with mastectomy rate and likelihood of achieving ypT0.</div></div><div><h3>Results</h3><div>In total, 5289 patients were included. Over 10 years, mastectomy rate significantly decreased from 62.6 % in 2010 to 35.1 % in 2019. Patients with IBC+DCIS more often underwent mastectomy, with a rate of 48.4 % in 2019, compared to 30.0 % in IBC only (p &lt; 0.001). Percentage of ypT0 was significantly lower in patients with IBC+DCIS (38.7 %), compared to IBC only (47.3 %, p &lt; 0.001) Multivariable logistic regression analyses showed presence of DCIS (OR 1.69, 95%CI 1.47–1.95, p &lt; 0.001) to be independently associated with mastectomy.</div></div><div><h3>Conclusion</h3><div>Rate of mastectomy decreased significantly in HER2+ IBC treated with NST between 2010 and 2019. Presence of DCIS in the biopsy remained associated with higher mastectomy rate, yet 38.7 % of these patients do achieve ypT0.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103854"},"PeriodicalIF":5.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adipocyte heterogeneity and tumor infiltration of adipose tissue in patients with metastatic breast cancer","authors":"Hava Izci ,&nbsp;Gitte Zels ,&nbsp;Anirudh Pabba ,&nbsp;Marion Maetens ,&nbsp;François Richard ,&nbsp;Maxim De Schepper ,&nbsp;Josephine Van Cauwenberge ,&nbsp;Ha-Linh Nguyen ,&nbsp;Kristien Borremans ,&nbsp;Sophia Leduc ,&nbsp;Karen Van Baelen ,&nbsp;Sigrid Hatse ,&nbsp;Tatjana Geukens ,&nbsp;Amena Mahdami ,&nbsp;Hans Wildiers ,&nbsp;Patrick Neven ,&nbsp;Wouter Van Den Bogaert ,&nbsp;Giuseppe Floris ,&nbsp;Christine Desmedt","doi":"10.1016/j.breast.2024.103852","DOIUrl":"10.1016/j.breast.2024.103852","url":null,"abstract":"<div><h3>Background</h3><div>The adipose tissue may serve as a source of energy supporting cancer growth and metastasis. Our understanding of the adipocytes which compose the adipose tissue in different anatomical locations of the body as well as potential microscopic tumor infiltration in patients with metastatic breast cancer remains limited. This study therefore investigates regional variations in adipocyte size and adipose tissue tumor infiltration in patients with metastatic breast cancer.</div></div><div><h3>Methods</h3><div>Within the UPTIDER rapid autopsy program, (NCT04531696), 94 adipose tissue samples from subcutaneous, visceral, retroperitoneal, and mammary depots of 22 patients with metastatic breast cancer were collected and analyzed. Distant adipocyte size was quantified using digital pathology, and tumor infiltration was assessed histologically. Linear mixed quantile regression analyzed the associations between adipocyte size, fat depot type and major histological subtypes.</div></div><div><h3>Results</h3><div>Distant adipocyte size did not significantly differ across fat depots. A trend towards smaller adipocytes in mammary fat at autopsy versus diagnosis was observed, suggesting potential age and/or treatment effects. Adipocyte size correlated positively with BMI at death, especially in subcutaneous and visceral fat. Visceral fat exhibited higher tumor infiltration, notably in patients with invasive lobular carcinoma (ILC).</div></div><div><h3>Conclusion</h3><div>This study highlights the relatively uniform adipocyte size across fat depots in patients with metastatic breast cancer, with potential changes in mammary adipocytes over the disease course. The microscopic tumor cell infiltration observed in the visceral fat, mainly for ILC, underscores the need to undertake additional research to understanding the contribution of the adipose tissue in breast cancer metastasis.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103852"},"PeriodicalIF":5.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis","authors":"Maria Inez Dacoregio ,&nbsp;Isabella Michelon ,&nbsp;Caio Ernesto do Rego Castro ,&nbsp;Francisco Cezar Aquino de Moraes ,&nbsp;Guilherme Rossato de Almeida ,&nbsp;Lis Victória Ravani ,&nbsp;Maysa Vilbert ,&nbsp;Ricardo Lima Barros Costa","doi":"10.1016/j.breast.2024.103853","DOIUrl":"10.1016/j.breast.2024.103853","url":null,"abstract":"<div><h3>Background</h3><div>Sacituzumab Govitecan (SG), a first-in-class anti-trophoblast cell surface antigen-2-directed antibody-drug conjugate (ADC), has shown clinically meaningful improvement in outcomes of patients with breast cancer (BC). However, it has also been accompanied by significant toxicity. Thus, we conducted a systematic review and meta-analysis to evaluate the safety and tolerability of SG in this patient population.</div></div><div><h3>Methods</h3><div>We comprehensively searched PubMed, Embase, and Cochrane databases, and ASCO and ESMO websites for clinical trials (CTs) assessing the safety of SG in BC patients. All analyses were performed in R software (v.4.2.2) using random effects models. Heterogeneity was assessed using I² test.</div></div><div><h3>Results</h3><div>Seven studies – three randomized clinical trials (RCTs) and four single-arm phase I/II – were included, comprising 928 patients receiving SG and 576 on treatment of physician's choice (TPC). Most patients had triple negative BC (54.4 %, n = 505), metastatic disease (89.8 %, n = 833), and were heavily pretreated (at least two lines of prior therapy). Most common all-grade adverse events (AEs) were: neutropenia (70 %, 95 % CI, 64–76 %), followed by nausea (62 %, 95 % CI, 55–68 %), diarrhea (54 %, 95 % CI 47–60 %) and anemia (51 %, 95 % CI, 38–65 %). Regarding high-grade AEs, 46 % of patients developed grade ≥3 neutropenia. Compared to TPC, we observed a higher risk of neutropenia (OR 3.11, 95 % CI 1.62–5.99, I² = 81 %; p &lt; 0.001), diarrhea (OR 6.82, 95 % CI 3.99–11.66, I² = 64 %; p &lt; 0.001) and anemia (OR 2.26, 95 % CI 1.20–4.27, I² = 78 %; p = 0.012) for those on SG. Dose reductions and treatment discontinuation were reported in 22 % and 4 % of patients, respectively, and 19 deaths (2 %) were documented. Most of them were not deemed to be treated-related.</div></div><div><h3>Conclusion</h3><div>This systematic review and meta-analysis provides extensive data on the safety and management of SG toxicity in BC patients across clinical trials. Concerning rates of neutropenia, nausea diarrhea, and anemia were reported. We highlight the need for protocols establishing prophylactic measures and strategies to mitigate SG-related toxicity.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103853"},"PeriodicalIF":5.7,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inequality in breast cancer: Global statistics from 2022 to 2050","authors":"Ling Liao","doi":"10.1016/j.breast.2024.103851","DOIUrl":"10.1016/j.breast.2024.103851","url":null,"abstract":"<div><div>This study evaluates the global inequalities of breast cancer incidence and mortality from 2022 to 2050 with the latest GLOBOCAN estimates. It focuses on disparities across continents, age groups and Human Development Index (HDI) levels. In 2022, Africa shows the highest positive slope values of age-standardized rates (world) of mortality vs. incidence, both for those under 40 (0.346) and those 40 and older (0.335). These values contrast with those for Asia (0.085, 0.208), Europe (0.002, −0.014), Latin America and the Caribbean (0.17, 0.303), Northern America (−0.078, −0.188), and Oceania (0.166, −0.001). In both age groups, lower HDI levels are correlated with higher slope values and vice versa. Projections to 2050 indicate significant increases in the burden of breast cancer, with persistent yet varied disparities and differences. This highlights the need for differentiated strategies in breast cancer prevention, early-stage diagnosis, and treatment.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103851"},"PeriodicalIF":5.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}